Overview
EMED Technologies designs, manufactures, and distributes subcutaneous infusion and drug-delivery systems for biologics and specialty drugs, mainly sold through B2B partnerships with pharmaceutical and healthcare companies. Its products include SCIg60 for home immunoglobulin infusion, VersaPump reusable syringe pumps, VersaRate flow controllers, and safety-oriented needle sets and inserters that enable home or clinic-based subcutaneous delivery; the company uses automated, AI-assisted manufacturing with strict quality control. EMED distinguishes itself through an end-to-end, integrated approach to product development and manufacturing for infusion solutions, its emphasis on home-based therapies, and collaborations with major manufacturers to scale production. The goal is to improve patient independence and quality of care by expanding its patient-centric infusion platforms and geographic reach, supported by strategic partnerships and new funding.
Work here?Claim your company
Simplify's take
What believers are saying
- EMED subsidiary closed an $8 million equity financing on February 24, 2026.
- EMED updated its website on October 5, 2026, signaling active commercialization.
- EMED added a Scientific Advisory Board and expanded VersaRate IP in 2025.
What critics are saying
- EMED's patent war with Repro-Med Systems remains open and expensive.
- Federal Circuit precedent already invalidated most of EMED's needle-shield claims in 2020.
- A VersaRate or needle-patent setback would erase EMED's moat and partner leverage.
What makes EMED Technologies unique
- EMED holds 15 patents across needle safety, insertion, and variable flow control.
- VersaRate gained U.S. Patent No. 12,403,243 on September 3, 2025.
- EMED supplies end-to-end subcutaneous infusion devices, assembly, labeling, and packaging worldwide.
Help us improve and share your feedback! Did you find this helpful?